Nivolumab Plus Ipilimumab or Nivolumab Alone vs Ipilimumab in Patients With Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
J. Clin. Oncol 2021 Nov 24;[EPub Ahead of Print], JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, CL Cowey, D Schadendorf, J Wagstaff, R Dummer, PF Ferrucci, M Smylie, MO Butler, A Hill, I Márquez-Rodas, JBAG Haanen, M Guidoboni, M Maio, P Schöffski, MS Carlino, C Lebbé, G McArthur, PA Ascierto, GA Daniels, GV Long, T Bas, C Ritchings, J Larkin, FS HodiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.